Zai Lab Yönetim
Yönetim kriter kontrolleri 2/4
Zai Lab CEO'su Samantha Du, Jan2014 tarihinde atandı, in görev süresi 12.33 yıldır. in toplam yıllık tazminatı $ 10.68M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.5% maaş ve 91.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1% ine doğrudan sahiptir ve bu hisseler $ 20.99M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 6.4 yıldır.
Anahtar bilgiler
Samantha Du
İcra Kurulu Başkanı
US$10.7m
Toplam tazminat
| CEO maaş yüzdesi | 8.51% |
| CEO görev süresi | 12.3yrs |
| CEO sahipliği | 1.0% |
| Yönetim ortalama görev süresi | 3.3yrs |
| Yönetim Kurulu ortalama görev süresi | 6.4yrs |
Son yönetim güncellemeleri
Recent updates
Analiz Makalesi • 15h
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...
Analiz Güncellemesi • May 01
ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion
The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China. Analyst Commentary Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.
Analiz Güncellemesi • Apr 16
ZLAB: Cautious China Outlook And Pipeline Progress Will Shape A Measured Re Rating
Analysts have lowered their average price targets on Zai Lab by several dollars, citing more cautious expectations for 2026 revenue growth. Management anticipates modest top line trends with pricing pressure and rising competition in China, which is reflected in slightly adjusted P/E assumptions and growth inputs.Seeking Alpha • Apr 06
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative
Summary On March 31, Zai Lab Limited stock finally broke out of its downward trend. One of the key factors behind this was the ZLAB announcement of a partnership agreement with Amgen. Moreover, I believe that the growing institutional investors' interest in Zai Lab is also driven by the strong performance of Zejula, Nuzyra, and Xacduro. So, Zejula, the leader within the PARPis class for the treatment of ovarian cancer, generated $56 million in revenue for Zai Lab in Q4, up 32.1% quarter-on-quarter. In this article, I have highlighted 3 more reasons explaining why I believe ZLAB stock's risk/reward profile is attractive. Read the full article on Seeking AlphaAnaliz Güncellemesi • Apr 02
ZLAB: Mixed Coverage And Pipeline Progress Will Shape A Measured Re Rating
Analysts have trimmed their price targets on Zai Lab, and the model update now points to a fair value of $21.80. This reflects expectations for more modest revenue growth and profit margins, along with a higher future P/E multiple.
Analiz Güncellemesi • Mar 19
ZLAB: China Approvals And Oncology Pipeline Progress Will Support Future Upside Potential
Analysts have trimmed their price targets on Zai Lab by up to $18, reflecting more cautious assumptions on revenue growth and competitive pressures. At the same time, updated models incorporate a higher projected profit margin and a lower future P/E multiple.Analiz Güncellemesi • Mar 04
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Narrative Update The updated analyst price target for Zai Lab has moved down from $67.22 to $55.00 as analysts factor in more modest projected revenue growth, lower profit margins, a higher assumed discount rate, and recent Street research pointing to pricing pressure, competition in China, and adjustments to company models following management commentary. Analyst Commentary Recent Street research on Zai Lab shows a mix of recalibrated price targets and ongoing constructive views on execution and longer term growth prospects.Analiz Güncellemesi • Feb 17
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Analysts trimmed their price targets on Zai Lab by $3.03, reflecting updated fair value and P/E assumptions, as well as fresh views on the company following recent research coverage changes. Analyst Commentary Recent Street research on Zai Lab has sent a mixed message, with some optimism around longer term potential but also fresh caution on how the current share price lines up with execution risks and valuation assumptions.Analiz Güncellemesi • Feb 03
ZLAB: Fresh Coverage And Pipeline Progress Will Support A Re Rating
The updated analyst price target for Zai Lab moves to about US$23.45 from about US$28.14, as analysts factor in lower revenue growth assumptions and a lower future P/E multiple, partly offset by higher projected profit margins and supported by fresh coverage and a US$35 target from recent Street research. Analyst Commentary While the updated blended price target for Zai Lab sits around US$23.45, investor sentiment is being pulled in different directions.Analiz Güncellemesi • Jan 20
ZLAB: Pipeline And New China Approvals Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Zai Lab to US$67.22 per share, reflecting slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E following fresh coverage initiation and list changes in recent Street research. Analyst Commentary Street research on Zai Lab has been mixed recently, but the latest fair value update and fresh coverage suggest that some bullish analysts still see room for upside relative to current pricing.Analiz Güncellemesi • Jan 06
ZLAB: Pipeline Execution After Conviction List Removal Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Zai Lab from US$74.00 to US$67.22, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples following its removal from a regional conviction list by a major broker. Analyst Commentary Goldman Sachs removed Zai Lab from its APAC Conviction List as part of a broader monthly review, which has prompted some investors to reassess expectations and risk appetite around the stock.Analiz Güncellemesi • Dec 20
ZLAB Removed From Conviction List Yet Future Pipeline Progress May Re-Rate Shares
Analysts have cut their price target on Zai Lab from approximately $39 to about $28, reflecting a materially lower growth outlook and higher perceived risk, as evidenced by its recent removal from a major APAC conviction list. Analyst Commentary Bearish analysts have interpreted the removal of Zai Lab from a major APAC conviction list as a signal that the company may face a more challenging path to justifying a premium valuation, particularly given rising competition and execution uncertainties in its pipeline and commercialization strategy.Analiz Güncellemesi • Dec 06
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Narrative Update on Zai Lab Analysts have moderately lowered their price target on Zai Lab to approximately $49.49, reflecting more conservative assumptions for revenue growth and profit margins, along with the stock’s recent removal from a key regional conviction list. Analyst Commentary Recent research updates on Zai Lab have prompted a more nuanced view of the company’s risk and reward profile, with analysts highlighting both supportive fundamentals and execution challenges that could influence the stock’s re-rating trajectory.Analiz Güncellemesi • Nov 22
ZLAB: Pipeline Diversification And Ongoing Partnerships Will Support Long-Term Market Expansion
Zai Lab's analyst price target has been revised downward from approximately $53.40 to $49.49. Analysts cite concerns over slowing revenue growth and narrowing profit margins.Analiz Makalesi • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Analiz Makalesi • Nov 07
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB)
Market forces rained on the parade of Zai Lab Limited ( NASDAQ:ZLAB ) shareholders today, when the analysts downgraded...Analiz Güncellemesi • Nov 07
ZLAB: Future Product Launches Will Drive Broader Market Reach And Patient Access
Analysts have lowered their price target for Zai Lab from approximately $55.41 to $53.40. They cite adjustments in key financial projections and the company's recent removal from a major conviction list as supporting factors.Analiz Makalesi • Nov 06
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analiz Makalesi • Oct 05
Is Zai Lab (NASDAQ:ZLAB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Güncellemesi • Sep 23
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41. Analyst Commentary Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.Analiz Makalesi • Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%
Zai Lab Limited ( NASDAQ:ZLAB ) shares have had a really impressive month, gaining 33% after a shaky period beforehand...
Yeni Analiz • Apr 30
New VYVGART And Pipeline Advances Will Expand Global Markets
Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.Seeking Alpha • Mar 20
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Summary ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB’s main growth drivers. ZLAB’s ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. ZLAB’s balance sheet is pretty solid, with close to 2.4 years of runway, and aiming towards profitability by yearend 2025. ZLAB’s valuation is higher than when I first covered it. New trade risks between the US and China also exist, but I remain bullish at these levels. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders have had their patience rewarded with a 31% share price jump in the last...Analiz Makalesi • Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Zai Lab Limited ( NASDAQ:ZLAB ) is a stock worth...Seeking Alpha • Dec 26
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Summary Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. Zai Lab's unique market position and strong pipeline make it a compelling investment for those with high risk tolerance. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Zai Lab Limited ( NASDAQ:ZLAB ) shares in the week since its...Analiz Makalesi • Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zai Lab Limited ( NASDAQ:ZLAB ) shares have continued their recent momentum with a 26% gain in the last month alone...Analiz Makalesi • Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Key Insights Zai Lab will host its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha...Analiz Makalesi • May 14
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Apr 16
A Risky Bet: Zai Lab's Uncertain Future
Summary Zai Lab offers a weaker value proposition for investors looking to bet on Chinese biotech due to its pure license in approach, limiting its potential to tap into global market. Its key products have shown a slow-down in 2023 and is facing increased competition. There is limited excitement in the current pipeline, as competitors have already taken the lead in the development timeline. The company is overvalued because it is trading at a similar P/S ratio to its peers, even though it has weaker quality in several key aspects. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Unfortunately for some shareholders, the Zai Lab Limited ( NASDAQ:ZLAB ) share price has dived 29% in the last thirty...Analiz Makalesi • Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$178m |
| Dec 31 2025 | US$11m | US$909k | -US$176m |
| Sep 30 2025 | n/a | n/a | -US$207m |
| Jun 30 2025 | n/a | n/a | -US$213m |
| Mar 31 2025 | n/a | n/a | -US$252m |
| Dec 31 2024 | US$9m | US$901k | -US$257m |
| Sep 30 2024 | n/a | n/a | -US$271m |
| Jun 30 2024 | n/a | n/a | -US$298m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$12m | US$869k | -US$335m |
| Sep 30 2023 | n/a | n/a | -US$301m |
| Jun 30 2023 | n/a | n/a | -US$393m |
| Mar 31 2023 | n/a | n/a | -US$410m |
| Dec 31 2022 | US$20m | US$830k | -US$443m |
| Sep 30 2022 | n/a | n/a | -US$593m |
| Jun 30 2022 | n/a | n/a | -US$529m |
| Mar 31 2022 | n/a | n/a | -US$554m |
| Dec 31 2021 | US$15m | US$774k | -US$704m |
| Sep 30 2021 | n/a | n/a | -US$569m |
| Jun 30 2021 | n/a | n/a | -US$537m |
| Mar 31 2021 | n/a | n/a | -US$454m |
| Dec 31 2020 | US$9m | US$689k | -US$269m |
| Sep 30 2020 | n/a | n/a | -US$239m |
| Jun 30 2020 | n/a | n/a | -US$240m |
| Mar 31 2020 | n/a | n/a | -US$201m |
| Dec 31 2019 | US$9m | US$656k | -US$195m |
Tazminat ve Piyasa: Samantha 'nin toplam tazminatı ($USD 10.68M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.48M ).
Tazminat ve Kazançlar: Samantha şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Samantha Du (59 yo)
12.3yrs
Görev süresi
US$10,677,221
Tazminat
Dr. Ying Du, Ph D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China.Dr. Du serves as an adjunct professor at Fudan Univ...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 12.3yrs | US$10.68m | 1% $ 21.0m | |
| President & COO | 3.8yrs | US$4.70m | 0.10% $ 2.2m | |
| President and Head of Global Research & Development | 3.3yrs | US$4.01m | 0.051% $ 1.1m | |
| Chief Financial Officer | 2.8yrs | US$3.19m | 0.028% $ 589.7k | |
| Chief Legal Officer & Corporate Secretary | 5.8yrs | US$3.28m | 0.021% $ 434.7k | |
| Senior VP & Head of Investor Relations | 3yrs | Veri yok | Veri yok | |
| Chief Operating Officer of R&D | 11.3yrs | Veri yok | Veri yok | |
| Chief Commercial Officer of Greater China | 2.1yrs | Veri yok | Veri yok | |
| Senior VP & Chief Business Officer | less than a year | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim: ZLAB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 12.3yrs | US$10.68m | 1% $ 21.0m | |
| Director | 6.3yrs | US$479.74k | 0.065% $ 1.4m | |
| Independent Director | 9.3yrs | US$482.49k | 0.35% $ 7.3m | |
| Lead Independent Director | 9.3yrs | US$513.61k | 0.089% $ 1.9m | |
| Independent Director | 4.6yrs | US$474.99k | 0.031% $ 642.4k | |
| Member of Oncology Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Director | 7.6yrs | US$456.11k | 0.031% $ 653.1k | |
| Member of Oncology Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 3.3yrs | US$472.97k | 0.045% $ 937.7k | |
| Independent Director | 4.5yrs | US$465.94k | 0.050% $ 1.1m | |
| Member of Oncology Scientific Advisory Board | 6.4yrs | Veri yok | Veri yok | |
| Independent Director | 12.3yrs | Veri yok | Veri yok |
6.4yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ZLAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 05:46 |
| Gün Sonu Hisse Fiyatı | 2026/05/11 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Zai Lab Limited 34 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Bo Li | BofA Global Research |